Improved lipid profiles and maintenance of virologic control in heavily pretreated hiv-infected patients who switched from stavudine to tenofovir treatment

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 145-147

  Schewe, Carl Knud ^a   Maserati, Renato ^c   Wassmer, Gernot ^b   Adam, Axel ^a   Weitner, Lutwin ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG SUBSTITUTION; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POLYNEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; STAVUDINE;

EID: 29244440843     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498516     Document Type: Article

References (9)

1. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. 903 Study Group. JAMA 2004; 292: 191-201.
2. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine-to tenofovir-containing regimens. J Acquir Immune Defic Sydr 2003; 33:544-6.
3. Schewe CK, Adam A, Weitner L, Meyer T. Evaluation of efficacy and safety of tenofovir DF (TDF) after switch from stavudine (d4T) in 93 chronically HIV-1 infected patients [poster 9.8/2], In: Program and abstracts of the 9th European AIDS Conference (Warsaw, Poland). Paris: European AIDS Society, 2003:83.
4. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. Recover Study Group. AIDS 2004; 18:1475-8.
5. Madruga JVR, Cassetti I, Suleiman JMAH, et al. Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48-week follow-up from Study 903E [poster TuPe2.2B12]. In: Program and abstracts of the 3rd International AIDS Society Conference (Rio de Janeiro, Brazi). Geneva: International AIDS Society, 2005:175.
6. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-36.
7. Moyle G, Sabin C, Cartledge J, et al. A randomised, open-label comparative trial of abacavir or tenofovir DF as replacement for a thymidine analogue in persons with lipoatrophy and suppressed HIV RNA on HAART: the RAVE Study [abstract 44LB]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:81.
8. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-15.
9. Benn P, Sauret V, Cartledge J, et al. Improvements in facial lipoatrophy at 48 weeks following substitution of a thymidine analog with tenofovir DF (TDF) or abacavir (ABC): a randomised, open-label study in persons with lipoatrophy and virological suppression on HAART [poster TuPe LB2.3C02]. In: Program and abstracts of the 3rd IAS Conference (Rio de Janeiro, Brazil). 2005.